Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Oct / Playing Chicken With Chicken
Microbiology & Immunology Microbiology and Immunology Profession Regulation and standards Professional Development

Playing Chicken With Chicken

Why is antibiotic resistance in Campylobacter species on the rise – and how can we combat it?

By Michael Schubert 10/21/2016 1 min read

Share

Credited with nearly one million cases of food poisoning each year in the United States alone (1), it’s no surprise that Campylobacter species are the major causes of foodborne gastroenteritis worldwide. Perhaps less well known is the fact that the species responsible for most human disease, C. jejuni and C. coli, are rapidly increasing their ability to resist antibiotics. This is a major problem: with Campylobacter contamination present on an estimated half of commercially available chickens (2), and over half of those bacteria resistant to common drugs like ciprofloxacin and nalidixic acid, it’s becoming more and more difficult to treat cases of campylobacteriosis.

The increase in resistance is at least partly due to the routine use of fluoroquinolone antibiotics in poultry farming. The drugs are used to treat or even prevent disease in chickens raised in crowded environments, where a single outbreak of infection can result in significant cost to the farm. But they’re also used to treat food poisoning in human patients – and if farming practices render the bacteria resistant to fluoroquinolones, doctors will lose one of their best options for eliminating human intestinal infections. What can be done? Some countries, including the United States and Australia, ban the drugs completely in the poultry industry. In those that don’t already have a ban in place, experts recommend that fluoroquinolone use be phased out. Organizations like the British Poultry Council have declared a commitment to reducing antibiotic use, and state that it’s already decreasing (3) – so hopefully,

C. jejuni and C. coli will escape their fate as an object lesson in the effect that agricultural overprescription can have on human disease…

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. NO Kaakoush et al., “Global epidemiology of Campylobacter infection”, Clin Microbiol Rev, 28, 687–720 (2015). PMID: 26062576. Food Standards Agency, “Year 2 of a UK-wide survey of campylobacter contamination on fresh chickens at retail (July 2015 to March 2016)”. Available at: http://bit.ly/208JCJO. Accessed October 15, 2016. M Davies, “Soaring levels of antibiotic resistance found in supermarket chickens” (2016). Available at: http://bit.ly/2d5OxgH. Accessed October 15, 2016.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Context Matters in Cancer Biology
Microbiology and Immunology
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

What’s New in Infectious Disease? (December 2021)
Microbiology and Immunology
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Microbiology and Immunology
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

2021: A Laboratory Medicine Roundup
Microbiology and Immunology
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.